146.60
price down icon0.14%   -0.22
 
loading
Johnson & Johnson stock is currently priced at $146.60, with a 24-hour trading volume of 1.29M. It has seen a -0.14% decreased in the last 24 hours and a -5.88% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $147.6 pivot point. If it approaches the $145.6 support level, significant changes may occur.
Previous Close:
$146.82
Open:
$146.7
24h Volume:
1.29M
Market Cap:
$353.80B
Revenue:
$89.66B
Net Income/Loss:
$40.58B
P/E Ratio:
10.88
EPS:
13.47
Net Cash Flow:
$17.78B
1W Performance:
-0.88%
1M Performance:
-5.88%
6M Performance:
-1.60%
1Y Performance:
-9.85%
1D Range:
Value
$145.95
$147.18
52W Range:
Value
$143.13
$175.97

Johnson & Johnson Stock (JNJ) Company Profile

Name
Name
Johnson & Johnson
Name
Phone
732-524-0400
Name
Address
One Johnson & Johnson Plaza, New Brunswick, NJ
Name
Employee
134,000
Name
Twitter
@jnjnews
Name
Next Earnings Date
2024-05-14
Name
Latest SEC Filings
Name
JNJ's Discussions on Twitter

Johnson & Johnson Stock (JNJ) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-18-24 Upgrade HSBC Securities Hold → Buy
Dec-13-23 Downgrade Wells Fargo Overweight → Equal Weight
Dec-01-23 Upgrade UBS Neutral → Buy
Oct-05-23 Initiated RBC Capital Mkts Outperform
Sep-06-23 Initiated HSBC Securities Hold
May-30-23 Resumed Citigroup Buy
Mar-29-23 Initiated UBS Neutral
Mar-01-23 Initiated Guggenheim Neutral
Nov-18-22 Initiated Credit Suisse Neutral
Oct-18-22 Initiated Barclays Equal Weight
Oct-14-22 Reiterated BofA Securities Neutral
Jun-22-22 Initiated Daiwa Securities Outperform
May-23-22 Resumed SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Mar-16-22 Downgrade Bernstein Outperform → Mkt Perform
Mar-02-22 Resumed BofA Securities Neutral
Dec-17-21 Initiated Goldman Neutral
Dec-15-21 Reiterated Citigroup Buy
Sep-07-21 Downgrade Morgan Stanley Overweight → Equal-Weight
May-28-21 Resumed Morgan Stanley Overweight
Apr-28-20 Downgrade UBS Buy → Neutral
Apr-22-20 Upgrade BofA/Merrill Neutral → Buy
Mar-05-20 Initiated Citigroup Buy
Dec-19-19 Upgrade Barclays Equal Weight → Overweight
Dec-17-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-20-19 Initiated Cantor Fitzgerald Overweight
Oct-16-19 Upgrade Atlantic Equities Underweight → Neutral
Oct-11-19 Upgrade Bernstein Mkt Perform → Outperform
Jul-12-19 Resumed Credit Suisse Outperform
May-28-19 Initiated Goldman Buy
Jan-23-19 Reiterated Barclays Equal Weight
Jul-12-18 Upgrade Goldman Sell → Neutral
Jun-27-18 Initiated Bernstein Mkt Perform
Apr-23-18 Reiterated Citigroup Neutral
Apr-18-18 Reiterated Stifel Hold
Jan-24-18 Reiterated Stifel Hold
Jan-12-18 Reiterated Wells Fargo Outperform
Jan-02-18 Downgrade JP Morgan Overweight → Neutral
Oct-18-17 Reiterated RBC Capital Mkts Outperform
Oct-18-17 Reiterated Stifel Hold
View All

Johnson & Johnson Stock (JNJ) Financials Data

Johnson & Johnson (JNJ) Revenue 2024

JNJ reported a revenue (TTM) of $89.66 billion for the quarter ending March 31, 2024, a +1.08% rise year-over-year.
loading

Johnson & Johnson (JNJ) Net Income 2024

JNJ net income (TTM) was $40.58 billion for the quarter ending March 31, 2024, a +218.89% increase year-over-year.
loading

Johnson & Johnson (JNJ) Cash Flow 2024

JNJ recorded a free cash flow (TTM) of $17.78 billion for the quarter ending December 31, 2023, a +3.45% increase year-over-year.
loading

Johnson & Johnson (JNJ) Earnings per Share 2024

JNJ earnings per share (TTM) was $14.34 for the quarter ending March 31, 2024, a +200.00% growth year-over-year.
loading

Johnson & Johnson Stock (JNJ) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Broadhurst Vanessa
EVP, Global Corp Affairs
Mar 13 '24
Sale
162.16
8,891
1,441,765
15,043
JOHNSON & JOHNSON
10% Owner
Feb 29 '24
Option Exercise
0.72
3,855
2,792
4,103,430
JOHNSON & JOHNSON
10% Owner
Feb 16 '24
Sale
25.81
3,725
96,142
4,099,575
Decker Robert J
VP Corporate Controller
Feb 13 '24
Option Exercise
0.00
313
0
19,059
Broadhurst Vanessa
EVP, Global Corp Affairs
Feb 13 '24
Option Exercise
0.00
408
0
24,143
Forminard Elizabeth
Executive VP, General Counsel
Feb 13 '24
Option Exercise
0.00
651
0
8,576
Duato Joaquin
CEO and Chairman of the Board
Feb 13 '24
Option Exercise
0.00
3,470
0
364,809
Hait William
See Remarks
Feb 13 '24
Option Exercise
0.00
834
0
39,074
Fasolo Peter
Exec VP, Chief HR Officer
Feb 13 '24
Option Exercise
0.00
925
0
112,550
Schmid Timothy
EVP, WW Chair, MedTech
Feb 13 '24
Option Exercise
0.00
499
0
13,290
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
drug_manufacturers_general MRK
$130.97
price up icon 0.32%
$160.98
price down icon 3.74%
drug_manufacturers_general NVS
$98.00
price down icon 1.07%
$269.73
price up icon 0.24%
drug_manufacturers_general PFE
$25.35
price up icon 0.34%
Cap:     |  Volume (24h):